Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Copaxone (Glatiramer) Available In UK For Relapsing-Remitting Multiple Sclerosis JERUSALEM, ISRAEL -- December 6, 2000 -- Teva Pharmaceutical Industries, Ltd., announced that Copaxone® was launched in the U.K., the product's first major European market. Copaxone (glatiramer acetate for injection) is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis (RR-MS). There are approximately 85,000 patients in the U.K of which 30,000 are RR-MS patients. Copaxone will be jointly marketed in the U.K. by Teva and Aventis. Peter Cardy, Chief Executive of the U.K. MS Society said: "The MS Society welcomes the availability of another therapy which can improve the quality of life for many people with MS." Recent published results of a six-year follow-up trial with Copaxone - the only organized MS therapeutic trial ever to be maintained for such a long duration in RR-MS patients - demonstrated a sustained clinical benefit and its safety profile. Copaxone has been approved for marketing in 19 countries including the U.S., Israel, Canada, Australia and Switzerland and has been used worldwide in over 30,000 patients. In the U.S., the major market of the product, Copaxone is the fastest growing multiple sclerosis therapy, outpacing the overall MS drug market with a market share exceeding 25 percent. Related Links: Copaxone (glatiramer acetate) and Teva Pharmaceutical Industries, Ltd. E-mail this page to a friend or colleague! To print, use this version